Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials

  • By

  • Bruce Strober

  • Mark Lebwohl

  • Peter van de Kerkhof

  • Linda Stein Gold

  • Joseph F. Merola

  • Yukari Okubo

  • Paolo Gisondi

  • Zhenwei Zhou

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Ulrich Mrowietz

  • October 2, 2026

Share

Original Source(s)

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials

  • by Bruce Strober, Mark Lebwohl, Peter van de Kerkhof, Linda Stein Gold, Joseph F. Merola, Yukari Okubo, Paolo Gisondi, Zhenwei Zhou, Siddharth Chaudhari, Cynthia Deignan, Ulrich Mrowietz

  • October 2, 2026

Related Content

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review